Pharmacokinetics and Bioequivalence of Two Formulations of Valsartan 80 mg Capsules: A Randomized, Single Dose, 4-Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions

References

• CriscioneL, de GasparoM, BuhlmayerP, WhitebreadS, RamjoueHP, WoodJ. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol. 1993;110(2):761–771.8242249
   PubMed Web of Science ®Google Scholar
• MarkhamA, GoaKL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997;54(2):299–311. doi:10.2165/00003495-199754020-000099257084
   PubMed Web of Science ®Google Scholar
• SpannellaF, GiuliettiF, BaliettiP, et al. Renin-angiotensin system blockers and statins are associated with lower in-hospital mortality in very elderly hypertensives. J Am Med Dir Assoc. 2018;19(4):342–347. doi:10.1016/j.jamda.2017.09.02329128438
   PubMed Web of Science ®Google Scholar
• ThomopoulosC, ParatiG, ZanchettiA. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35(5):922–944. doi:10.1097/HJH.000000000000127628141660
   PubMed Web of Science ®Google Scholar
• Federal food, drug, and cosmetic act, chapter v, subchapter a, drugs and devices section 355(j)(8)(B)(i).
   Google Scholar
• ZaidAN, CortesiR, QaddomiA, KhammashS. Formulation and bioequivalence of two valsartan tablets after a single oral administration. Sci Pharm. 2011;79(1):123–135. doi:10.3797/scipharm.1009-0121617777
   PubMedGoogle Scholar
• DIOVAN^®(Valsartan) Capsules [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.
   Google Scholar
• YamadaI, GodaT, KawataM, ShiotukiT, OgawaK. Gastric acidity-dependent bioavailability of commercial sustained release preparations of indomethacin, evaluated by gastric acidity-controlled beagle dogs. Chem Pharm Bull. 1990;38(11):3112–3115. doi:10.1248/cpb.38.3112
   PubMed Web of Science ®Google Scholar
• MansouriK, BehloulS, CheraitI, NekhoulK, HadjazIM, MansouriMB. Bioequivalence of two brands of valsartan 80 mg coated breakable tablets in 15 healthy algerian volunteers: a pilot study. J Pharm Pharmacol. 2017;661–667.
   Google Scholar
• SaydamM, TakkaS. Bioavailability File: valsartan, FABAD. J Pharm Sci. 2007;32(4):185–196.
   Google Scholar
• National Medical Products Administration of China, Center for Drug Evaluation. Guideline for bioavailability and bioequivalence studies of generic drug products [in Chinese]. 2019.
   Google Scholar
• ColussiDM, ParisotC, RossolinoML, BrunnerLA, LefevreGY. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol. 1997;37(3):214–221. doi:10.1002/j.1552-4604.1997.tb04783.x9089423
   PubMed Web of Science ®Google Scholar
• FleschG, MullerP, LloydP. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997;52(2):115–120. doi:10.1007/s0022800502599174680
   PubMed Web of Science ®Google Scholar
• KimJE, KiMH, YoonIS, et al. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: a randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. Clin Ther. 2014;36(2):273–279. doi:10.1016/j.clinthera.2014.01.00424529292
   PubMed Web of Science ®Google Scholar
• IqbalM, KhurooA, BatolarLS, TandonM, MonifT, SharmaPL. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Clin Ther. 2010;32(3):588–596. doi:10.1016/j.clinthera.2010.03.00420399995
   PubMed Web of Science ®Google Scholar
• MullerP, FleschG, de GasparoM, GaspariniM, HowaldH. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol. 1997;52(6):441–449.9342579
   PubMed Web of Science ®Google Scholar
• SioufiA, MarfilF, JaouenA, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos. 1998;19(4):237–244. doi:10.1002/(SICI)1099-081X(199805)19:4<237::AID-BDD100>3.0.CO;2-79604123
   PubMed Web of Science ®Google Scholar
• SechaudR, GrafP, BiglerH, GruendlE, LetzkusM, MerzM. Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design. Int J Clin Pharmacol Ther. 2002;40(1):35–40.11837381
   PubMed Web of Science ®Google Scholar
• SpinolaAC, AlmeidaS, FilipeA, NevesR, TrabelsiF, FarreA. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Clin Ther. 2009;31(9):1992–2001. doi:10.1016/j.clinthera.2009.09.00219843489
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki (WMA). Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 7, 2000. Accessed, 2019.
   Google Scholar
• International Council for Harmonization of technical requirements for registration of pharmaceuticals for human use. Accessed, 2019.
   Google Scholar
• National Medical Products Administration of China. Guideline for good clinical practice [in Chinese]. Accessed, 2019.
   Google Scholar
• HanpithakpongW, KamanikomB, DondorpAM, et al. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876(1):61–68. doi:10.1016/j.jchromb.2008.10.018
   PubMed Web of Science ®Google Scholar
• HodelEM, ZanolariB, MercierT, et al. A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(10):867–886. doi:10.1016/j.jchromb.2009.02.006
   PubMed Web of Science ®Google Scholar
• National Medical Products Administration of China. Technical guideline for clinical pharmacokinetics of chemical drugs [in Chinese]. Accessed, 2019.
   Google Scholar
• DavitBM, ChenML, ConnerDP, et al. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J. 2012;14(4):915–924. doi:10.1208/s12248-012-9406-x22972221
   PubMed Web of Science ®Google Scholar
• HoweWG. Approximate confidence limits on the mean of X+Y where X and Y are two tabled independent variables. J Amer Statist Assoc. 1974;69:789–794.
   Web of Science ®Google Scholar